Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity
المؤلفون المشاركون
Chae, Hyojin
Koh, Yoon-Seok
Hwang, Byung-Hee
Kang, Min-Kyu
Kim, Yonggoo
Park, Hae-il
Chang, Kiyuk
Kim, Myungshin
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-03-28
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Clopidogrel is a prodrug which is converted into active metabolite by cytochrome P450 isoenzyme, CYP2C19.
Numerous polymorphisms of CYP2C19 are reported, and a strong link exists between loss-of-function (LOF) or gain-of-function polymorphisms, clopidogrel metabolism, and clinical outcome.
Hence, a fully automated point-of-care CYP2C19 genotyping assay is more likely to bring personalized antiplatelet therapy into real practice.
We assessed the feasibility of the Verigene 2C19/CBS Nucleic Acid Test, a fully automated microarray-based assay, compared to bidirectional sequencing, and performed VerifyNow P2Y12 assay to evaluate the effect of CYP2C19 polymorphisms on on-treatment platelet reactivity in 57 Korean patients treated with clopidogrel after percutaneous coronary intervention.
The Verigene 2C19/CBS assay identified *2, *3, and *17 polymorphisms with 100% concordance to bidirectional sequencing in 180 minutes with little hands-on time.
Patients were classified into 4 groups: extensive (*1/*1; n=12, 21.1%), intermediate (*1/*2, *1/*3; n=33, 57.9%), poor (*2/*2, *2/*3, and *3/*3; n=11, 19.3%), and ultrarapid metabolizers (*1/*17; n=1, 1.8%).
The prevalence of the CYP2C19 *2, *3, and *17 alleles was 36.0%, 12.3%, and 0.9%.
Platelet reactivity showed gene dose response according to the number of CYP2C19 LOF allele.
In conclusion, the Verigene 2C19/CBS assay gave accurate CYP2C19 genotype results which were in well match with the differing on-treatment platelet reactivity.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Chae, Hyojin& Kim, Myungshin& Koh, Yoon-Seok& Hwang, Byung-Hee& Kang, Min-Kyu& Kim, Yonggoo…[et al.]. 2013. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International،Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Chae, Hyojin…[et al.]. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International No. 2013 (2013), pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Chae, Hyojin& Kim, Myungshin& Koh, Yoon-Seok& Hwang, Byung-Hee& Kang, Min-Kyu& Kim, Yonggoo…[et al.]. Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-5.
https://search.emarefa.net/detail/BIM-1030134
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1030134
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر